Syndyma (Bevacizumab) Injection
It is approved for the treatment of: Colorectal Cancer: Metastatic cancer of the colon or rectum. Lung Cancer: Advanced non-squamous, non-small cell lung cancer (NSCLC). Brain Tumors: Recurrent or progressive glioblastoma multiforme. Kidney Cancer: Advanced or metastatic renal cell carcinoma (often alongside interferon alfa). Female Reproductive Cancers: Cervical, epithelial ovarian, fallopian tube, and primary peritoneal cancers. Breast Cancer: Persistent, recurrent, or metastatic breast cancer. Liver Cancer: Hepatocellular carcinoma. Bevacizumab Injection (Brand name Syndyma) is available in Delhi, India. Product Name Syndyma Salt Composition Bevacizumab Injection Product Form / Net Quantity Injection 100 mg/4ml Marketed By Cipla Availability In Stock at Aark Locations Prescription Requi
About Syndyma (Bevacizumab) Injection
Description Is Bevacizumab Injection available in India? Yes, Bevacizumab Injection is available in India. It is marketed under the brand name Syndyma among others. It is a monoclonal antibody medication used to treat a number of types of cancers and a s pecific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal). Common side effects when used for cancer include nose bleeds, headache, high blood pressure, and rash. Other severe side effects include gastrointestinal perforation, bleeding, allergic reactions, blood clots, and an increased risk of infection. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A), in other words anti–VEGF therapy. Bevacizumab was approved for medical use in the United States in 2004 . It is on the World Health Organization’s List of Essential Medicines It is listed for its use in treating eye disease. Who is the CFA, distributor, and retailer for Syndyma (Bevacizumab) Injection in India? Aark Pharmaceuticals is an authorized distributor, CFA (Carry and Forward Agent), and retailer for Syndyma (Bevacizumab) Injection in India. It is marketed by Cipla . Aark claims to provide 100% authentic, cold-chain managed medicines. Aark supplies a wide range of Cipla products , including advanced cancer treatments. The company serves hospitals, clinics, and patients across India, including major cities like Bangalore, Surat, Kolkata, Indore, Nagpur, Patiala, Srinagar, Ahmedabad, Osmanabad, Mumbai, Pune, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Coimbatore, Kochi, Kollam, Agartala, Lucknow, Dehradun, Gairsain, Aizawal, Aurangabad, Barshi, Karungapally, Pondichery, Punjab, Delhi, New Delhi, Agra, Kanpur, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad, Wardha, Bhopal, Manipur, Mizoram, Sikkim, Tripura, Arunachal, Meghalaya, Nagaland, Pasighat, Cachar, Dibrugarh, Kamrup. How much do Syndyma Injection cost in Delhi, India? Prices may vary based on your prescribed treatment plan. For accurate and the most cost-effective pricing on your prescription-recommended product, please contact Aark Pharmaceuticals Seller Name: Aark Pharmaceuticals Private Limited. Contact Person: Ms. Himanshi Address: S-14, Ground & Ist Floor, Green Park Extn., New Delhi-110016. Mobile / WhatsApp : 9999156233 Email: sales@aarkpharma.co.in , sales@aarkpharma.com Our Branch Offices in India – New Delhi | Lucknow | Varan
